Targeting enzyme could block cancer spread to brain with fewer side effects

Researchers have developed novel drug candidates that target a key enzyme responsible for cancer metastasis to the brain, according to a study published in the Proceedings of the National Academy of Sciences. The breakthrough focuses on preventing lung, breast, skin, and other cancers from spreading to the brain while minimizing harmful side effects. This advancement builds on promising therapeutic strategies reported by the same research team last year. The more precise approach offers hope for improving outcomes in patients with advanced cancers that are prone to brain metastasis.